Authors:
MARKOWITZ M
CONANT M
HURLEY A
SCHLUGER R
DURAN M
PETERKIN J
CHAPMAN S
PATICK A
HENDRICKS A
YUEN GJ
HOSKINS W
CLENDENINN N
HO DD
Citation: M. Markowitz et al., A PRELIMINARY EVALUATION OF NELFINAVIR MESYLATE, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 PROTEASE, TO TREAT HIV-INFECTION, The Journal of infectious diseases, 177(6), 1998, pp. 1533-1540
Authors:
YUEN GJ
ANDERSON R
SANDOVAL T
WU E
SHETTY BV
KERR BM
Citation: Gj. Yuen et al., THE PHARMACOKINETICS (PK) OF NELFINAVIR(N) ADMINISTERED ALONE AND WITH RIFAMPIN (RIF) IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 40-40
Authors:
KERR BM
YUEN GJ
SANDOVAL T
WU E
SHETTY BV
ANDERSON R
Citation: Bm. Kerr et al., THE PHARMACOKINETICS (PK) OF NELFINAVIR(N) ADMINISTERED ALONE AND WITH KETOCONAZOLE(K) IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 42-42
Authors:
HEALD AE
HSYU PH
YUEN GJ
ROBINSON P
MYDLOW P
BARTLETT JA
Citation: Ae. Heald et al., PHARMACOKINETICS OF LAMIVUDINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH RENAL DYSFUNCTION, Antimicrobial agents and chemotherapy, 40(6), 1996, pp. 1514-1519
Authors:
MOORE KHP
YUEN GJ
RAASCH RH
ERON JJ
MARTIN D
MYDLOW PK
HUSSEY EK
Citation: Khp. Moore et al., PHARMACOKINETICS OF LAMIVUDINE ADMINISTERED ALONE AND WITH TRIMETHOPRIMSULFAMETHOXAZOLE, Clinical pharmacology and therapeutics, 59(5), 1996, pp. 550-558
Citation: Gj. Yuen et al., POPULATION (POP) PHARMACOKINETICS (PK) OF LAMIVUDINE (3TC) IN HIV-INFECTED PATIENTS - RESULTS FROM 2 PHASE-III CLINICAL-TRIALS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 60-60
Authors:
YUEN GJ
MORRIS DM
MYDLOW PK
HAIDAR S
HALL ST
HUSSEY EK
Citation: Gj. Yuen et al., PHARMACOKINETICS, ABSOLUTE BIOAVAILABILITY, AND ABSORPTION CHARACTERISTICS OF LAMIVUDINE, Journal of clinical pharmacology, 35(12), 1995, pp. 1174-1180
Authors:
YUEN GJ
DRUSANO GL
FLETCHER C
CAPPARELLI E
CONNOR JD
LALEZARI JP
DREW L
FOLLANSBEE S
BUSCH D
JACOBSON M
SPECTOR SA
SQUIRES K
BUHLES W
Citation: Gj. Yuen et al., POPULATION DIFFERENCES IN GANCICLOVIR CLEARANCE AS DETERMINED BY NONLINEAR MIXED-EFFECTS MODELING, Antimicrobial agents and chemotherapy, 39(10), 1995, pp. 2350-2352
Authors:
PLUDA JM
COOLEY TP
MONTANER JSG
SHAY LE
REINHALTER NE
WARTHAN SN
RUEDY J
HIRST HM
VICARY CA
QUINN JB
YUEN GJ
WAINBERG MA
RUBIN M
YARCHOAN R
Citation: Jm. Pluda et al., A PHASE I II STUDY OF 2'-DEOXY-3'-THIACYTIDINE (LAMIVUDINE) IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION/, The Journal of infectious diseases, 171(6), 1995, pp. 1438-1447